Background: The significance of uncommon epidermal growth factor receptor (EGFR)
mutations in patients with non-small cell lung cancer (NSCLC) and brain metastasis (BM) …

Central nervous system (CNS) progression is frequently detected in patients with favorable
initial responses to first-generation epidermal growth factor receptor-tyrosine kinase …

Purpose Brain metastasis is common in patients with epidermal growth factor receptor
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …

This study compared treatment outcomes between TKI monotherapy and TKI administration
combined with brain radiotherapy (TKI+ RT) in 133 non-small cell lung cancer (NSCLC) …

Objective: This study aimed to investigate the potential use of icotinib as first-line treatment
to prevent brain metastasis from advanced lung adenocarcinoma. Patients and Methods …

Introduction Non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor
(EGFR) mutation has a higher incidence of brain metastases than wild‐type EGFR …

Purpose Non-small cell lung cancer (NSCLC) patients with EGFR mutation are suffering
from a high incidence of brain metastasis (BM). It is still controversial whether cranial …

Introduction The efficacy of tyrosine kinase inhibitors (TKIs) with and without radiotherapy
(RT) has not been determined in patients with brain metastases from epidermal growth …

Brain parenchymal metastasis from a solid tumor is a serious clinical condition associated
with a poor outcome because systemic chemotherapy is usually ineffective for treating brain …

Objectives Central nervous system (CNS) metastases are common complications in
epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) …